A hypoattenuating lesion of the liver is an area that appears darker than the surrounding liver tissue on a CT scan. It shows up this way because it absorbs fewer X-rays than normal liver, which can happen for many reasons: fluid-filled cysts, fatty deposits, benign growths, or sometimes tumors. The term itself is purely descriptive, not a diagnosis. It tells your radiologist that something in the liver looks different, but not what it is.
These findings are common. Studies report that incidental liver lesions show up on CT scans in 7% to 33% of all patients being scanned, and the vast majority turn out to be harmless. Still, the term can be alarming when you see it on a radiology report, so understanding what it means and what comes next is worth your time.
Why Some Liver Tissue Looks Darker on CT
CT scanners measure tissue density in Hounsfield Units (HU). Healthy liver tissue typically falls in a predictable range. When an area measures significantly lower, it appears as a dark spot on the image. A simple fluid-filled cyst, for example, measures between 0 and 20 HU, well below normal liver. An area with excess fat can drop below 10 HU. Even some solid masses appear darker than surrounding tissue because their internal composition (blood vessels, dead cells, or abnormal tissue) absorbs X-rays differently.
The degree of “darkness,” the shape of the lesion, and how it behaves when contrast dye is injected all help radiologists narrow down what they’re looking at. A single snapshot isn’t usually enough. That’s why many CT reports recommend additional imaging or note findings across different phases of the scan.
Common Benign Causes
Simple Cysts
The most straightforward explanation for a hypoattenuating liver lesion is a simple cyst, a fluid-filled sac with thin walls. On CT, cysts appear as uniform, low-density structures (under 20 HU) with sharp edges and no enhancement after contrast dye is given. They require no treatment and are considered a normal variant when they meet these criteria. They’re especially common in older adults and are often found incidentally during scans done for unrelated reasons.
Hemangiomas
Hemangiomas are clusters of blood vessels that form a benign mass. They’re the most common solid liver lesion. On an unenhanced CT, they appear as sharply defined hypoattenuating areas. What distinguishes them is their behavior with contrast dye: they show a characteristic pattern of bright enhancement starting at the edges and slowly filling inward toward the center over several minutes. This “fill-in” pattern is distinctive enough that radiologists can usually identify hemangiomas with confidence on a multi-phase CT scan.
Focal Nodular Hyperplasia
Focal nodular hyperplasia (FNH) is a benign growth made of normal liver cells arranged around an abnormal central blood vessel. It usually appears only slightly darker than normal liver on unenhanced CT, and about a third of cases show a characteristic low-density central scar. FNH is more common in women and almost never requires treatment, though its appearance can sometimes overlap with other lesions, prompting further imaging with MRI.
Focal Fatty Deposits
Sometimes the liver stores fat unevenly, creating patches that look like lesions on CT. These focal fatty deposits can mimic benign or even malignant masses, which makes them an important consideration. Several features help distinguish fat from a true mass: fatty areas tend to have wedge-shaped or geometric margins, they don’t push nearby blood vessels out of the way, and they follow the shape of liver segments rather than forming a round ball. When there’s doubt, MRI can confirm fat by using a technique that shows signal loss on specific sequences. Fat deposits also don’t restrict the movement of water molecules on diffusion-weighted imaging, a feature that helps separate them from more concerning lesions.
When a Lesion May Be Malignant
While most incidental hypoattenuating liver lesions are benign, certain features raise concern for cancer. The two main possibilities are a primary liver cancer (one that starts in the liver) and metastatic disease (cancer that has spread from somewhere else).
Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and occurs predominantly in people with chronic liver disease, such as cirrhosis or chronic hepatitis B or C. On a multi-phase CT scan, HCC has a hallmark two-part behavior: it lights up brightly during the arterial phase (when contrast dye first arrives through the arteries) and then fades, or “washes out,” during the later portal venous or delayed phases. This arterial-phase brightness followed by washout is so characteristic that the American College of Radiology built its liver imaging classification system (LI-RADS) around it. Vascular invasion, where tumor tissue grows into nearby blood vessels, is another feature that points strongly toward HCC.
Liver Metastases
The liver is one of the most common sites for cancer to spread because it filters large volumes of blood from the rest of the body. Metastatic lesions tend to be hypoattenuating on non-contrast studies and often appear as multiple lesions rather than a single one. The most common primary cancers that spread to the liver are colorectal cancer, followed by pancreatic and breast cancers. Certain contrast-enhanced patterns also help identify metastases: peripheral washout on delayed images, where the edges of a lesion lose contrast while the center retains it, is a feature characteristic of malignancy and can be seen in both metastases and bile duct cancers (cholangiocarcinoma).
Context matters enormously. A single small hypoattenuating lesion found incidentally in someone with no cancer history and no liver disease has a very different significance than a similar finding in someone being treated for colon cancer. Radiologists weigh these clinical details heavily when deciding what to recommend next.
How Size and Number Affect Next Steps
Lesion size plays a major role in determining whether follow-up is needed. Very small lesions, often called “too small to characterize,” are common and usually benign. They’re frequently under 1 centimeter and lack enough detail on CT for a radiologist to confidently determine what they are. In patients without known cancer or chronic liver disease, these are typically left alone or monitored with a follow-up scan months later to confirm they haven’t changed.
Lesions larger than 1 centimeter generally warrant closer evaluation because they’re large enough to show distinguishing features. The next step often involves a contrast-enhanced, multi-phase CT or an MRI, which provides better soft-tissue detail. MRI is particularly useful for characterizing lesions because it can detect fat, fluid, and scar tissue with greater precision than CT. In patients with known chronic liver disease, the American College of Radiology notes that standard single-phase CT is usually not sufficient, and dedicated liver imaging protocols are preferred.
Multiple hypoattenuating lesions scattered across the liver raise more concern than a solitary one, especially in patients with a known primary cancer elsewhere. However, multiple cysts or hemangiomas are also common and completely benign, so multiplicity alone doesn’t confirm malignancy.
What Happens After the Finding
If your CT report mentions a hypoattenuating liver lesion, the radiologist will typically include a recommendation based on what they see. For lesions that clearly meet the criteria for a simple cyst (uniform fluid density, sharp margins, no enhancement), no further workup is needed. For lesions that look like classic hemangiomas with the expected fill-in pattern, the same applies.
When a lesion can’t be confidently classified on the initial scan, the most common next step is an MRI of the liver with contrast. MRI can distinguish between fat, fluid, blood products, and solid tissue in ways that CT cannot, and it does so without additional radiation exposure. In some cases, contrast-enhanced ultrasound is used as an alternative.
Biopsy is rarely the first step. Imaging alone can characterize most liver lesions accurately. Biopsy is typically reserved for cases where imaging remains inconclusive and the clinical stakes are high, such as when the finding could change cancer treatment decisions. For the large majority of people who see “hypoattenuating lesion” on a scan report, the finding will either be clearly benign or easily clarified with one additional imaging study.